A SHORT REVIEW ON 3D IN PHARMACEUTICAL INDUSTRY: A STATE OF THE ART FOR BETTERMENT OF INDUSTRY

Vijay Kumar Pal, Dr. Piyush Yadav

Prasad institute of technology, Jaunpur, U.P., India

Abstract

3D printing, also known as additive manufacturing, has revolutionized the pharmaceutical industry by enabling the fabrication of personalized, complex, and patient-centric drug delivery systems. This review highlights the evolution, principles, and applications of 3D printing in pharmaceuticals, including tailored dosage forms, polypills, controlled-release systems, implants, and bioprinted tissues. The technology offers advantages such as customization, rapid prototyping, cost efficiency, and enhanced patient compliance, while challenges remain in the areas of material limitations, print accuracy, regulatory frameworks, scalability, and ethical considerations. Emerging trends, including integration with artificial intelligence, digital health, and bioprinting, promise to further expand its impact on precision medicine and advanced therapies. Addressing these challenges through standardization, quality control, and evidence-based regulatory guidelines will be critical for widespread adoption. Overall, 3D printing represents a state-of-the-art approach poised to transform pharmaceutical manufacturing and patient care.

Keywords: *3D printing, additive manufacturing, pharmaceuticals, personalized medicine, drug delivery*

Corresponding Author

Vijay Kumar Pal

Received: 25/06/2026
Revised: 10/07/2026
Accepted: 28/07/2026
DOI: http://doi.org/10.66204/GJPSR-1302-2026-2-8-7

How to Cite
Pal VK, Yadav P. A Short Review on 3D in Pharmaceutical Industry: A State of the Art for Betterment of Industry. Global Journal of Pharmaceutical and Scientific Research. 2026; 2(8):1302-1316. ISSN: 3108-0103. http://doi.org/10.66204/GJPSR-1302-2026-2-8-7.

1. INTRODUCTION

The advent of 3D printing technology, also known as additive manufacturing, has transformed multiple industrial sectors, including healthcare and pharmaceuticals. 3D printing is a layer-by-layer fabrication process that enables the creation of complex structures from digital designs, allowing precise control over geometry, composition, and dosage forms (Melocchi et al., 2020). Unlike traditional manufacturing, which relies on subtractive processes or molds, 3D printing allows rapid prototyping, flexibility, and personalization, making it highly suitable for the pharmaceutical sector, where dosage customization and patient-specific therapies are increasingly demanded (Jamróz et al., 2018).

1.1 Background of 3D Technology

3D printing emerged in the 1980s as a manufacturing innovation for creating prototypes and models (Hull, 1986). Over the decades, it has evolved into additive manufacturing, encompassing various techniques such as fused deposition modeling (FDM), stereolithography (SLA), selective laser sintering (SLS), and inkjet printing. These techniques vary in their mechanisms but share a common principle: layer-wise deposition of materials guided by a digital blueprint (Gross et al., 2014).

In the pharmaceutical context, 3D printing provides the capability to produce complex drug geometries, multi-drug tablets, and dosage forms with precise drug release profiles, which is difficult to achieve with conventional tableting and encapsulation methods (Goyanes et al., 2015). Additionally, 3D printing enables on-demand manufacturing, which reduces storage costs and enhances accessibility, particularly in remote or low-resource settings.

1.2 Evolution of 3D Printing in Pharmaceuticals

The integration of 3D printing in pharmaceutical sciences began in the early 21st century, driven by the need for personalized medicine and innovative drug delivery systems. In 2015, the U.S. Food and Drug Administration (FDA) approved Spritam® (levetiracetam), the first 3D-printed drug, which demonstrated rapid disintegration and patient-centric dosing, marking a significant milestone in pharmaceutical 3D printing (Skowyra et al., 2015).

Since then, research has focused on multi-drug polypills, controlled-release systems, transdermal patches, and implants, demonstrating that 3D printing can enhance therapeutic efficacy, improve compliance, and enable combination therapies in a single dosage form (Patel et al., 2020). Advances in material science, digital modeling, and bioprinting techniques have further expanded its scope, including the development of tissue-engineered products and implantable drug-delivery devices.

1.3 Importance and Scope in the Pharmaceutical Industry

The pharmaceutical industry faces challenges such as high costs of drug development, lengthy production timelines, and increasing demand for personalized therapy. 3D printing addresses these issues by enabling:

- **Personalized Dosage Forms:** Tailoring doses to patient-specific needs, age, or pharmacogenomics (Goyanes et al., 2017).
- **Complex Drug Release Profiles:** Producing immediate, sustained, or multi-phase release in a single dosage form (Melocchi et al., 2020).
- **Rapid Prototyping and Small-Batch Manufacturing:** Facilitating faster formulation testing and on-demand production, reducing waste and inventory costs.
- **Innovation in Drug Combinations and Implants:** Enabling polypills, combination therapies, and customized implants with precise drug distribution (Patel et al., 2020).

These advantages position 3D printing as a disruptive technology in the pharmaceutical industry, capable of improving patient compliance, therapeutic outcomes, and manufacturing efficiency. The scope of 3D printing extends from conventional oral dosage forms to novel drug delivery systems, implantable devices, and bioprinted tissues, making it a critical area of research and industrial development (Jamróz et al., 2018).

2. Fundamentals of 3D Printing Technology

3D printing, also known as additive manufacturing, is revolutionizing pharmaceutical manufacturing by enabling the creation of customized dosage forms, complex geometries, and multi-drug systems. Understanding its definition, principles, techniques, and materials is essential for appreciating its applications and impact in the pharmaceutical industry.

2.1 Definition and Principle of 3D Printing

3D printing is a layer-by-layer fabrication process that constructs three-dimensional objects from digital designs using computer-aided design (CAD) software (Gross et al., 2014). Unlike traditional subtractive manufacturing, which removes material from a block, additive manufacturing adds material precisely where needed, allowing for highly complex and patient-specific structures.

In pharmaceuticals, 3D printing enables tailored drug release profiles, dosage personalization, and novel formulation design. The process generally involves designing a digital model, selecting suitable materials, and sequentially depositing them layer-by-layer, followed by post-processing to achieve the final dosage form (Melocchi et al., 2020).

2.2 Types of 3D Printing Techniques Used in Pharma

Several 3D printing techniques have been adapted for pharmaceutical applications, each with distinct principles, advantages, and limitations:

2.2.1 Fused Deposition Modeling (FDM)

FDM is one of the most commonly used 3D printing techniques in pharma. It involves extruding a thermoplastic polymer filament through a heated nozzle to form layers according to a digital design (Goyanes et al., 2017). Advantages include simplicity, cost-effectiveness, and suitability for personalized tablets with modified release profiles. Limitations include material constraints and potential thermal degradation of heat-sensitive drugs.

2.2.2 Stereolithography (SLA)

SLA uses a photopolymer resin that solidifies upon exposure to ultraviolet (UV) light, allowing high-resolution printing with fine surface finishes (Jamróz et al., 2018). SLA is useful for fabricating complex oral dosage forms, implants, and drug-loaded devices, but it requires careful selection of biocompatible photopolymers and may involve extensive post-processing.

2.2.3 Selective Laser Sintering (SLS)

SLS employs a laser beam to sinter powdered material, fusing particles layer-by-layer to build the structure. In pharmaceuticals, SLS enables rapid production of complex drug geometries without using binders or solvents (Awad et al., 2018). This technique is advantageous for rapid prototyping and oral dosage forms but requires high-powered lasers and precise thermal control.

2.2.4 Inkjet Printing

Inkjet printing deposits liquid formulations drop-wise onto a substrate, enabling precise dosing and multi-drug combination tablets (Fina et al., 2017). This method is particularly suitable for orally disintegrating films and polypills. Challenges include formulation viscosity limitations, nozzle clogging, and solvent compatibility.

2.3 Materials Used in Pharmaceutical 3D Printing

The choice of material is critical for 3D printing in pharmaceuticals. Commonly used materials include:

- Polymers: Such as polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), and polyethylene glycol (PEG) for filament-based or resin-based printing.
- Photopolymers: Biocompatible resins for SLA and other light-based methods.
- Powders: Drug-excipient blends for SLS or powder-bed printing.

- Liquid formulations: Solutions or suspensions for inkjet printing, including polymers, solvents, and active pharmaceutical ingredients (Fina et al., 2017; Melocchi et al., 2020).

Material selection affects drug stability, release profile, printability, and biocompatibility, making it essential to match the printing technique with formulation characteristics.

3. Applications of 3D Printing in Pharmaceuticals

3D printing technology has introduced significant innovations in the pharmaceutical industry by enabling personalized therapy, complex dosage forms, and advanced drug delivery systems. Its applications range from patient-specific tablets to implants and tissue-engineered products, addressing challenges in conventional drug manufacturing and improving therapeutic outcomes.

3.1 Personalized Medicine and Tailored Dosage Forms

3D printing facilitates customized drug dosing based on patient-specific factors such as age, weight, metabolic profile, and comorbidities. Traditional manufacturing methods are limited to fixed dosages, whereas 3D printing allows rapid production of tablets with precise drug content, suitable for pediatrics, geriatrics, or patients with unique therapeutic requirements (Goyanes et al., 2017).

For example, Spritam® (levetiracetam), the first FDA-approved 3D-printed drug, demonstrates rapid disintegration and personalized dosing, enabling patient-centric therapy (Skowyra et al., 2015). Digital design enables adjustable tablet geometry and drug distribution, supporting individualized medicine.

3.2 Controlled and Sustained Drug Release Systems

3D printing enables precise control over drug release profiles, allowing immediate, delayed, or multi-phase release from a single dosage form. By modifying internal geometry, porosity, or polymer composition, 3D-printed tablets can achieve sustained therapeutic effects while reducing dosing frequency (Melocchi et al., 2020).

Such control over release kinetics enhances treatment efficacy, patient adherence, and reduces side effects, particularly for chronic conditions requiring consistent plasma drug levels. Techniques like FDM and SLA are widely used for engineered matrix tablets and multi-layered drug systems.

3.3 Fixed-Dose Combinations and Polypills

3D printing allows the combination of multiple active pharmaceutical ingredients (APIs) in a single dosage unit, addressing polypharmacy issues and simplifying patient regimens.

Polypills can be engineered with distinct drug compartments, each with specific release profiles (Jamróz et al., 2018).

This approach is particularly beneficial for elderly patients and those with chronic diseases, improving adherence and therapeutic efficiency while reducing medication errors. Digital layering techniques ensure spatial separation of incompatible drugs and flexibility in designing combination therapies.

3.4 Implants, Medical Devices, and Tissue Engineering

3D printing supports the production of drug-eluting implants, stents, and tissue-engineered scaffolds. These devices can be tailored in shape, size, and drug loading, providing site-specific therapy and enhanced patient outcomes (Awad et al., 2018).

Bioprinting, an emerging 3D printing application, enables fabrication of cell-laden scaffolds for tissue regeneration, combining regenerative medicine with localized drug delivery. Such innovations hold promise for orthopedic, cardiovascular, and wound-healing applications, bridging the gap between pharmaceutical therapy and medical devices.

3.5 Novel Formulations and Complex Drug Design

3D printing allows creation of dosage forms previously impossible with conventional manufacturing, including hollow tablets, multi-compartment systems, and gradient drug loading designs (Fina et al., 2017).

These novel formulations enable fine-tuning of pharmacokinetics, improved solubility for poorly soluble drugs, and multi-drug combinations with controlled interactions. Additionally, 3D printing can support orally disintegrating films, chewable tablets, and pediatric-friendly formulations, enhancing patient acceptability and adherence.

4. Advantages of 3D Printing in the Pharmaceutical Industry

3D printing offers transformative benefits to pharmaceutical manufacturing, enabling innovation, efficiency, and patient-centered solutions. Compared to conventional methods, it provides flexibility, precision, and the ability to tailor therapies to individual patient needs.

4.1 Customization and Patient-Centric Therapy

One of the most significant advantages of 3D printing is the ability to customize dosage forms according to patient-specific requirements. Dosage strength, shape, size, and release profile can be precisely tailored to individual age, weight, metabolic rate, or genetic profile (Goyanes et al., 2017).

For example, pediatric and geriatric patients often require non-standard doses or formulations (like chewable tablets or orally disintegrating films), which can be easily produced via 3D

printing. Personalized tablets can also combine multiple drugs into a single polypill, improving adherence and therapeutic outcomes (Jamróz et al., 2018).

4.2 Rapid Prototyping and Production Efficiency

3D printing enables rapid prototyping of new formulations, allowing researchers to quickly test tablet design, drug release profiles, and dosage forms without relying on time-consuming traditional production methods (Melocchi et al., 2020).

This approach reduces development timelines and enables iterative optimization of drug products. Small-batch production is also feasible, supporting on-demand manufacturing and reducing inventory requirements. Rapid prototyping is particularly valuable for clinical trials and personalized therapy development.

4.3 Reduction in Drug Development Costs

By minimizing material waste, streamlining production, and enabling on-demand manufacturing, 3D printing can significantly reduce drug development costs (Fina et al., 2017). Traditional pharmaceutical manufacturing involves large-scale batch production, extensive tooling, and high storage costs, all of which are mitigated through additive manufacturing.

Moreover, digital design files can be transferred across locations, facilitating global production with minimal infrastructure, which is particularly beneficial for emerging markets or personalized therapies.

4.4 Enhanced Drug Safety and Compliance

3D printing enhances drug safety and patient compliance by enabling precise dosing and minimizing errors associated with manual tablet splitting or compounding (Skowyra et al., 2015).

Customized release profiles (immediate, sustained, or multi-phase) improve therapeutic outcomes and reduce side effects. Polypills produced via 3D printing simplify complex medication regimens, particularly for elderly patients with multiple comorbidities, ensuring better adherence.

5. Challenges and Limitations

Despite the promising applications and advantages of 3D printing in pharmaceuticals, several challenges limit its widespread adoption. These challenges are technical, regulatory, economic, and ethical, and addressing them is essential for the safe, scalable, and effective implementation of this technology.

5.1 Technical Challenges (Material Limitations, Print Accuracy)

The success of 3D printing depends heavily on materials and printing precision. Not all pharmaceutical excipients or drugs are compatible with current 3D printing techniques. For example, heat-sensitive drugs may degrade during fused deposition modeling (FDM), while photopolymers used in SLA may require extensive post-processing to ensure biocompatibility (Melocchi et al., 2020).

Print accuracy is another concern, especially for multi-drug polypills or complex geometries, where deviations can impact drug dosage and release profiles. Layer adhesion, resolution limitations, and post-processing variability can affect reproducibility, posing challenges for clinical application (Jamróz et al., 2018).

5.2 Regulatory and Quality Control Issues

Regulatory frameworks for 3D-printed pharmaceuticals are still evolving. Traditional Good Manufacturing Practice (GMP) standards may not fully address additive manufacturing processes (Patel et al., 2020). Key concerns include:

- Standardization of printing protocols
- Batch-to-batch consistency and quality assurance
- Stability and uniformity of printed drugs

FDA-approved examples, like Spritam®, show that regulatory acceptance is possible, but broader adoption requires global harmonization of guidelines, testing protocols, and quality control measures (Skowyra et al., 2015).

5.3 Cost and Scalability Concerns

While 3D printing reduces material waste and enables on-demand production, initial investment in printers, software, and materials is high (Fina et al., 2017). Scaling production for commercial purposes remains challenging because most printers are designed for small-batch or laboratory use, and throughput is lower compared to conventional manufacturing methods.

High operational costs, including maintenance, skilled labor, and quality testing, can hinder adoption in large-scale pharmaceutical production, particularly in resource-limited settings.

5.4 Intellectual Property and Ethical Issues

3D printing introduces complex intellectual property (IP) concerns. Digital design files can be easily shared or copied, raising questions about patent protection and drug piracy (Awad et al., 2018).

Ethical issues also arise around personalized medicine, including equitable access, patient privacy for digital health records, and potential misuse of bioprinting technologies (Patel et al., 2020). Ensuring ethical application requires clear guidelines, legal frameworks, and monitoring at both national and international levels.

6. Regulatory Framework and Guidelines

The implementation of 3D printing in pharmaceuticals is closely linked to regulatory oversight. Ensuring safety, quality, and efficacy is critical for patient protection and the credibility of additive manufacturing in medicine. Regulatory frameworks are still evolving globally to accommodate this novel technology.

6.1 Regulatory Status Globally (FDA, EMA, etc.)

The U.S. Food and Drug Administration (FDA) has been proactive in addressing 3D-printed pharmaceuticals. The FDA approved Spritam® (levetiracetam) in 2015, the first 3D-printed oral dosage form, setting a precedent for regulatory evaluation of additive manufacturing (FDA, 2015). The FDA emphasizes good manufacturing practices (GMP), quality control, and process validation for 3D-printed drugs, while encouraging innovation in personalized therapy.

The European Medicines Agency (EMA) has acknowledged the potential of 3D printing but requires compliance with existing pharmaceutical legislation, including rigorous risk assessment, stability testing, and quality assurance for novel dosage forms (EMA, 2017). Other countries, such as Japan and Canada, are gradually developing guidelines focusing on digital design validation, material safety, and batch-to-batch reproducibility (Goyanes et al., 2017).

6.2 Safety and Standardization Measures

Safety and standardization are major regulatory concerns. 3D-printed drugs must meet dosage uniformity, mechanical strength, dissolution, and stability criteria similar to conventionally manufactured drugs (Melocchi et al., 2020).

Key measures include:

- Validation of digital designs and printer settings to ensure reproducibility.
- Use of pharmacopeial-grade excipients compatible with 3D printing.
- Post-processing quality control, including content uniformity, disintegration, and dissolution testing.
- Traceability of materials and production parameters, essential for regulatory audits.

Adopting standardized protocols for materials, printing techniques, and testing is critical for global harmonization and safe commercialization (Patel et al., 2020).

6.3 Future Policy Directions

The regulatory landscape for 3D printing in pharmaceuticals is expected to evolve rapidly. Future directions include:

- International harmonization of guidelines, allowing global approval and commercialization.
- Integration of digital health technologies to track personalized dosage production and patient adherence.
- Promotion of research-based evidence to support regulatory decisions on novel formulations and bioprinted drugs.
- Ethical and intellectual property frameworks to manage digital design sharing and personalized therapy (Awad et al., 2018).

These initiatives aim to balance innovation with safety, enabling widespread adoption of 3D printing while maintaining high standards of patient care.

7. Future Perspectives and Research Directions

3D printing technology is rapidly evolving and promises to reshape the pharmaceutical industry. Its future lies not only in customized drug delivery but also in integration with digital health, artificial intelligence (AI), and bioprinting technologies, which could enable novel therapies and more efficient healthcare solutions.

7.1 Emerging Trends in 3D Printing for Pharma

Several emerging trends are likely to transform pharmaceutical manufacturing:

Personalized Polypills and Multi-Drug Delivery: Advanced 3D printing enables multi-compartmental dosage forms combining multiple drugs with different release profiles in a single tablet, improving patient adherence and minimizing polypharmacy issues (Patel et al., 2020).

On-Demand and Point-of-Care Manufacturing: Hospitals and pharmacies could produce patient-specific medications on-site, reducing supply chain dependency and enabling rapid response to shortages or emergencies (Goyanes et al., 2017).

Novel Dosage Form Design: Complex geometries, porous structures, and hollow tablets allow tailored dissolution rates, taste masking, and targeted release, expanding formulation possibilities beyond conventional methods (Melocchi et al., 2020).

Integration with Wearable and Smart Devices: 3D-printed formulations may be integrated with drug-eluting devices, sensors, and smart packaging, enabling real-time monitoring of medication adherence and therapy effectiveness.

7.2 Role of Artificial Intelligence and Digital Health Integration

The synergy between 3D printing and digital health technologies has immense potential:

AI-assisted Formulation Design: Machine learning algorithms can optimize drug-polymer combinations, layer architecture, and dosage release profiles, reducing trial-and-error in formulation development (Awad et al., 2018).

Predictive Manufacturing and Quality Control: AI can monitor printer parameters, detect anomalies, and predict batch quality, ensuring reproducibility and regulatory compliance.

Digital Health Platforms: Integration with patient data allows tailored treatment regimens, personalized dosing schedules, and remote therapy monitoring, improving patient outcomes (Patel et al., 2020).

This combination creates a smart, adaptive, and patient-centered pharmaceutical ecosystem, bridging precision medicine and additive manufacturing.

7.3 Potential for Bioprinting and Advanced Therapies

Bioprinting, a subfield of 3D printing, has enormous potential in tissue engineering, regenerative medicine, and organ-on-chip models:

Cell-Laden Constructs and Tissue Scaffolds: Bioprinting enables fabrication of living tissues and organ models, which can be loaded with drugs for localized therapy or testing drug efficacy and toxicity (Melocchi et al., 2020).

Personalized Implants and Prosthetics: 3D printing allows customized drug-eluting implants for bone repair, cardiovascular applications, or wound healing, offering targeted therapy with reduced systemic side effects (Awad et al., 2018).

Advanced Therapies: Future research may focus on printing multi-drug cancer implants, bioactive scaffolds, or organs for transplantation, integrating pharmaceutical sciences with regenerative medicine (Patel et al., 2020).

These advancements will push the boundaries of conventional pharmaceuticals, merging therapy, diagnostics, and tissue engineering in a single platform.

8. Conclusion

3D printing has emerged as a transformative technology in the pharmaceutical sector, enabling personalized medicine, complex drug delivery systems, and innovative formulations that were previously unattainable with conventional manufacturing methods. Its applications

span from tailored dosage forms and polypills to implants, medical devices, and bioprinted tissues, offering enhanced therapeutic efficacy, patient adherence, and safety.

Despite its advantages, challenges such as material limitations, regulatory uncertainties, production scalability, and ethical concerns must be addressed to ensure safe and widespread adoption. Ongoing research, integration with artificial intelligence, digital health, and bioprinting, promises to overcome these barriers, ushering in a new era of precision medicine. In conclusion, 3D printing represents a state-of-the-art approach for modern pharmaceutical development, with the potential to redefine drug manufacturing, regulatory paradigms, and patient-centric therapy in the near future. Continued innovation, coupled with robust regulatory frameworks, will be essential for realizing the full potential of this technology.

9. Acknowledgements

The authors would like to express their sincere gratitude to all the researchers and institutions whose work has contributed to the development of this review.

10. Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this review.

11. References

- 3D Printing in Healthcare: A Review on Drug Printing, Challenges and Future Perspectives. Materials Today Communications. 2024;40:110199.
- 3D Printing in Pharmaceutical Manufacturing: Current Status and Future Prospects. Materials Today Communications. 2024;38:107987. https://doi.org/10.1016/j.mtcomm.2023.107987
- A Review of 3D Printing Technology in Pharmaceutics: Technology and Applications, Now and Future. Pharmaceutics. 2023;15(2):416. https://doi.org/10.3390/pharmaceutics15020416
- Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharmaceutical Research. 2016.
- Awad, A., Trenfield, S., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). 3D printing: Principles and pharmaceutical applications. *Pharmaceutical Research, 35*(10), 193. https://doi.org/10.1007/s11095-018-2491-4
- European Medicines Agency (EMA). (2017). Reflection paper on the development of medicines for use in the paediatric population: 3D printing applications. EMA/CHMP/65755/2017.

- Fina, F., Goyanes, A., Gaisford, S., & Basit, A. W. (2017). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *Molecular Pharmaceutics, 14*(11), 3963–3970. https://doi.org/10.1021/acs.molpharmaceut.7b00444
- Food and Drug Administration (FDA). (2015). FDA approves first 3D-printed drug product. Retrieved from https://www.fda.gov/news-events/press-announcements
- Goyanes A, Buanz ABM, Basit AW, Gaisford S. Fused-Filament 3D Printing (3DP) for Fabrication of Tablets. International Journal of Pharmaceutics. 2014.
- Goyanes, A., Det-Amornrat, U., Wang, J., Basit, A. W., & Gaisford, S. (2017). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *Molecular Pharmaceutics, 14*(11), 3963–3970. https://doi.org/10.1021/acs.molpharmaceut.7b00444
- Gross, B. C., Erkal, J. L., Lockwood, S. Y., Chen, C., & Spence, D. M. (2014). Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. *Analytical Chemistry, 86*(7), 3240–3253. https://doi.org/10.1021/ac403397r
- Hull, C. W. (1986). Apparatus for production of three-dimensional objects by stereolithography. U.S. Patent No. 4,575,330.
- Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D Printing in Pharmaceutical and Medical Applications – Recent Achievements and Challenges. Pharmaceutical Research. 2018.
- Jamróz, W., Szafraniec, J., Kurek, M., & Jachowicz, R. (2018). 3D printing in pharmaceutical and medical applications – recent achievements and challenges. *Pharmaceutical Research, 35*(9), 176. https://doi.org/10.1007/s11095-018-2454-x
- Kumari S, Kumari P. Artificial Intelligence in Clinical Pharmacy: Present Uses and Potential Developments. Global Journal of Pharmaceutical and Scientific Research. 2026;2(5). ISSN: 3108-0103.
- Melocchi, A., Uboldi, M., Foppoli, A., Maroni, A., Gazzaniga, A., & Zema, L. (2020). 3D printing by fused deposition modeling of single- and multi-compartment hollow systems for oral delivery – A review. *International Journal of Pharmaceutics, 587*, 119672. https://doi.org/10.1016/j.ijpharm.2020.119672
- Muhindo D, Elkanayati R, Srinivasan P, Repka MA, Ashour EA. Recent Advances in the Applications of Additive Manufacturing (3D Printing) in Drug Delivery: A Comprehensive Review. AAPS PharmSciTech. 2023;24(2):57. https://doi.org/10.1208/s12249-023-02524-9

- Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. A New Chapter in Pharmaceutical Manufacturing: 3D-Printed Drug Products. Advanced Drug Delivery Reviews. 2017.
- Pal A, Maurya VK, Kumar K. Liposomes as Drug Delivery Systems: A Comprehensive Review with Recent Advances. Global Journal of Pharmaceutical and Scientific Research. 2026;2(7). ISSN: 3108-0103.
- Pandey M, Gupta D. 3D Printing in Pharmaceutics: Revolutionizing Drug Formulation and Manufacturing. Journal of Drug Discovery and Health Sciences. 2024. https://doi.org/10.21590/jddhs.01.04.04
- Patel, N., Feng, X., Liu, J., & Lu, Q. (2020). 3D printing of pharmaceuticals: A new paradigm in personalized medicine. *Advanced Drug Delivery Reviews, 169*, 82–103. https://doi.org/10.1016/j.addr.2020.05.003
- Prajapati AK, Maurya VK, Kumar K. Orodispersible Tablets: A Comprehensive Review of Formulation Strategies, Technologies and Recent Advances. Global Journal of Pharmaceutical and Scientific Research. 2026;2(7). ISSN: 3108-0103.
- Sawadi AMY, Alanazi AIH, Muaddi AA, et al. Advances and Innovations in 3D Printing Technologies for the Development of Customized Pharmaceutical Dosage Forms: A Comprehensive Review. Review of Contemporary Philosophy. 2024.
- Singh N, Kumar N. Nanocarrier-Based Delivery of 5-Fluorouracil in Breast Cancer: Targeting Tumor Microenvironment and Overcoming Chemoresistance. Global Journal of Pharmaceutical and Scientific Research. 2026;2(7):1021–1043. ISSN: 3108-0103.
- Skowyra, J., Pietrzak, K., & Alhnan, M. A. (2015). Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modeling (FDM) 3D printing. *European Journal of Pharmaceutics and Biopharmaceutics, 96*, 380–387. https://doi.org/10.1016/j.ejpb.2015.09.020.
- Tiwari S, Wasiullah M, Yadav P, Yadav V. Phytomedicine: The Role of AI in Phytomedicine. Global Journal of Pharmaceutical and Scientific Research. 2026;2(4). ISSN: 3108-0103.
- Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D Printing Pharmaceuticals: Drug Development to Frontline Care. Trends in Pharmacological Sciences. 2018.
- Vaz VM, Kumar L. 3D Printing as a Promising Tool in Personalized Medicine. AAPS PharmSciTech. 2021;22(1):49.

- Wang J, Goyanes A, Gaisford S, Basit AW. Emerging 3D Printing Technologies for Drug Delivery Devices: Current Status and Future Perspective. Advanced Drug Delivery Reviews. 2021;174:294–316. https://doi.org/10.1016/j.addr.2021.04.019
- Wasiullah M, Yadav P, Chauhan N, Maurya PD. A Building Block in the Pharmaceutical Industry: Quality Control and Quality Assurance. Global Journal of Pharmaceutical and Scientific Research. 2026;2(1):176–200. ISSN: 3108-0103.
- Yuvaraj AR, Jayadurka J, Elavarasi E, Srinivasan R. Applications and Advancement of 3D Printing in Pharmaceutical Manufacturing and Drug Delivery: Review Article. Journal of Pharma Insights and Research. 2024;2(3):23–29.